50 patents
Utility
ANTI-TREM2 Antibodies and Methods of Use Thereof
5 Oct 23
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Tina SCHWABE, Eric BROWN, Philip KONG, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
Filed: 24 Feb 23
Utility
ANTI-TMEM106B Antibodies and Methods of Use Thereof
28 Sep 23
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Arnon ROSENTHAL, Eric BROWN, Tina SCHWABE, Angie YEE, Herve RHINN
Filed: 18 Aug 22
Utility
ANTI-TREM2 Antibodies and Methods of Use Thereof
21 Sep 23
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Tina SCHWABE, Fracesca AVOGADRI-CONNORS, Helen LAM, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL
Filed: 17 Feb 23
Utility
Pilra Antibodies and Methods of Use Thereof
13 Jul 23
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PILRA and compositions comprising such antibodies or antigen-binding fragments thereof.
Spencer LIANG, Samuel NALLE, Ling LEUNG
Filed: 17 Feb 21
Utility
Methods of Use of ANTI-TREM2 Antibodies
25 May 23
The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.
Francesca CIGNARELLA, Fabia FILIPELLO, Bryan BOLLMAN, Arnon ROSENTHAL, Tina SCHWABE, Ilaria TASSI, Laura PICCIO
Filed: 23 Feb 21
Utility
ANTI-MS4A4A Antibodies and Methods of Use Thereof
11 May 23
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Philip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Ilaria TASSI, Muhammad Abbas ALHAWAGRI, Arnon ROSENTHAL
Filed: 19 Aug 22
Utility
ANTI-MS4A4A Antibodies and Methods of Use Thereof
27 Apr 23
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc.. that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Philip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Ilaria TASSI, Muhammad Abbas ALHAWAGRI, Arnon ROSENTHAL
Filed: 19 Aug 22
Utility
Anti-TREM1 Antibodies and Methods of Use Thereof
20 Apr 23
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Andrew Pincetic, Arnon Rosenthal, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee
Filed: 13 Sep 22
Utility
ANTI-TREM2 Antibodies and Methods of Use Thereof
6 Apr 23
The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2.
Kate MONROE, Tina SCHWABE, Francesca AVOGADRI-CONNORS, Ilaria TASSI, Helen LAM, Arnon ROSENTHAL
Filed: 21 Apr 22
Utility
Anti-sortilin Antibodies and Methods of Use Thereof
16 Feb 23
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
Filed: 9 Jun 22
Utility
Methods of Use of ANTI-CD33 Antibodies
2 Feb 23
The present disclosure is generally directed to antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics.
Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL
Filed: 11 Dec 20
Utility
Methods of Use of ANTI-TREM2 Antibodies
26 Jan 23
The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.
Tina SCHWABE, Ilaria TASSI, Arnon ROSENTHAL, Hua LONG, Santiago Viveros SALAZAR
Filed: 4 Dec 20
Utility
ANTI-SIGLEC-7 Antibodies and Methods of Use Thereof
29 Dec 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate MONROE, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Francesca AVOGADRI-CONNORS, William MONTEITH
Filed: 2 Jun 22
Utility
ANTI-MS4A6A Antibodies and Methods of Use Thereof
1 Dec 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, anti-body fragments, etc., that specifically bind a MS4A6A polypeptide, e g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Philip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Arnon ROSENTHAL
Filed: 18 Apr 22
Utility
Anti-sortilin Antibodies and Methods of Use Thereof
3 Nov 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
Filed: 9 Jun 22
Utility
ANTI-SIGLEC-5 Antibodies and Methods of Use Thereof
6 Oct 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate MONROE, Helen LAM, Patricia CULP, Arnon ROSENTHAL
Filed: 9 May 22
Utility
Anti-SIRPa Antibodies and Methods of Use Thereof
15 Sep 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
Filed: 29 Mar 22
Utility
ANTI-CD33 Antibodies and Methods of Use Thereof
8 Sep 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Arnon ROSENTHAL, Kate MONROE, Francesca AVOGADRI-CONNORS
Filed: 24 May 22
Utility
ANTI-CD33 Antibodies and Methods of Use Thereof
11 Aug 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate MONROE, Helen LAM, Francesca AVOGADRI-CONNORS, Seung-Joo LEE, William MONTEITH, Herve RHINN, Arnon ROSENTHAL
Filed: 27 Aug 21
Utility
Methods of Use of Anti-sortilin Antibodies for Treating a Disease, Disorder, or Injury
11 Aug 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
Filed: 14 Apr 22